V
Vincent C. Marconi
Researcher at Emory University
Publications - 224
Citations - 10171
Vincent C. Marconi is an academic researcher from Emory University. The author has contributed to research in topics: Population & Medicine. The author has an hindex of 41, co-authored 199 publications receiving 6875 citations. Previous affiliations of Vincent C. Marconi include Grady Memorial Hospital & San Antonio Military Medical Center.
Papers
More filters
Journal ArticleDOI
Code Saturation Versus Meaning Saturation: How Many Interviews Are Enough?
TL;DR: In this article, the authors compared two approaches to assess saturation: code saturation and meaning saturation, and examined sample sizes needed to reach saturation in each approach, what saturation meant, and how to assess it.
Journal ArticleDOI
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.
Andre C. Kalil,Thomas F. Patterson,Aneesh K. Mehta,Kay M. Tomashek,Cameron R. Wolfe,Varduhi Ghazaryan,Vincent C. Marconi,Guillermo M. Ruiz-Palacios,Lanny Hsieh,Susan Kline,Victor F. Tapson,Nicole M. Iovine,Mamta K. Jain,Daniel A. Sweeney,Hana M. El Sahly,Angela Branche,Justino Regalado Pineda,David C. Lye,Uriel Sandkovsky,Anne F Luetkemeyer,Stuart H. Cohen,Robert W. Finberg,Patrick E. H. Jackson,Babafemi Taiwo,Catharine I. Paules,Henry Arguinchona,Nathaniel B. Erdmann,Neera Ahuja,Maria G. Frank,Myoung Don Oh,Eu-Suk Kim,Seow Y Tan,Richard A. Mularski,Henrik Nielsen,Philip O Ponce,Barbara S. Taylor,LuAnn Larson,Nadine Rouphael,Youssef Saklawi,Valeria D Cantos,Emily R Ko,John J. Engemann,Alpesh Amin,Miki Watanabe,Joanne Billings,Marie-Carmelle Elie,Richard T. Davey,Timothy Burgess,Jennifer Ferreira,Michelle Green,Mat Makowski,Anabela Cardoso,Stephanie de Bono,Tyler Bonnett,Michael A. Proschan,Gregory A. Deye,Walla Dempsey,Seema U Nayak,Lori E. Dodd,John H. Beigel +59 more
TL;DR: Baricitinib plus remdesivir was superior to remdes Vivir alone in reducing recovery time and accelerating improvement in clinical status among patients with Covid-19, notably among those receiving high-flow oxygen or noninvasive ventilation.
Journal ArticleDOI
Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.
Vincent C. Marconi,Vincent C. Marconi,Athimalaipet V Ramanan,Stephanie de Bono,Cynthia E. Kartman,Venkatesh Krishnan,Ran Liao,Maria Lucia B. Piruzeli,Jason D Goldman,Jorge Alatorre-Alexander,Rita de Cassia Pellegrini,Vicente Estrada,Mousumi Som,Anabela Cardoso,Sujatro Chakladar,Brenda J. Crowe,Paulo Reis,Xin Zhang,David H. Adams,E. Wesley Ely +19 more
TL;DR: Baricitinib is an oral selective Janus kinase 1/2 inhibitor with known anti-inflammatory properties as discussed by the authors, which has been shown to reduce mortality in hospitalised adults with COVID-19.
Journal ArticleDOI
Clinical Outcomes of Elite Controllers, Viremic Controllers, and Long-Term Nonprogressors in the US Department of Defense HIV Natural History Study
Jason F. Okulicz,Jason F. Okulicz,Vincent C. Marconi,Vincent C. Marconi,Michael L. Landrum,Michael L. Landrum,Scott Wegner,Amy C. Weintrob,Amy C. Weintrob,Anuradha Ganesan,Braden R. Hale,Braden R. Hale,Nancy F. Crum-Cianflone,Nancy F. Crum-Cianflone,Judith Delmar,Vincent Barthel,Vincent Barthel,Gerald V. Quinnan,Brian K. Agan,Matthew J. Dolan +19 more
TL;DR: Durable control of human immunodeficiency virus replication and lack of disease progression in the absence of antiretroviral therapy were studied in a military cohort of 4586 subjects to describe distinct populations whose differing clinical outcomes improve with the stringency of criteria.
Journal ArticleDOI
Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa.
Vincent C. Marconi,Henry Sunpath,Zhigang Lu,Michelle Gordon,Kofi Koranteng-Apeagyei,Jane Hampton,Steve Carpenter,Janet Giddy,Douglas S. Ross,Helga Holst,Elena Losina,Bruce D. Walker,Bruce D. Walker,Daniel R. Kuritzkes,Daniel R. Kuritzkes +14 more
TL;DR: Antiretroviral drug-resistant virus was detected in >80% of South African patients who experienced failure of a first HAART regimen, and patterns of drug resistance reflected drugs used in first-line regimens and viral subtype.